KR20220131262A - 섬유증, 비대 또는 심부전의 치료 또는 예방에 사용하기 위한 골수-유래 성장 인자 - Google Patents

섬유증, 비대 또는 심부전의 치료 또는 예방에 사용하기 위한 골수-유래 성장 인자 Download PDF

Info

Publication number
KR20220131262A
KR20220131262A KR1020227027546A KR20227027546A KR20220131262A KR 20220131262 A KR20220131262 A KR 20220131262A KR 1020227027546 A KR1020227027546 A KR 1020227027546A KR 20227027546 A KR20227027546 A KR 20227027546A KR 20220131262 A KR20220131262 A KR 20220131262A
Authority
KR
South Korea
Prior art keywords
mydgf
heart failure
fibrosis
variant
hypertrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227027546A
Other languages
English (en)
Korean (ko)
Inventor
카이 크리스토프 볼러트
모티머 코르프-클링에비엘
마크 알. 레볼
안톤 펙섹
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20220131262A publication Critical patent/KR20220131262A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227027546A 2020-01-21 2021-01-19 섬유증, 비대 또는 심부전의 치료 또는 예방에 사용하기 위한 골수-유래 성장 인자 Pending KR20220131262A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20153008 2020-01-21
EP20153008.6 2020-01-21
PCT/EP2021/051079 WO2021148411A1 (en) 2020-01-21 2021-01-19 Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure

Publications (1)

Publication Number Publication Date
KR20220131262A true KR20220131262A (ko) 2022-09-27

Family

ID=69187588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227027546A Pending KR20220131262A (ko) 2020-01-21 2021-01-19 섬유증, 비대 또는 심부전의 치료 또는 예방에 사용하기 위한 골수-유래 성장 인자

Country Status (12)

Country Link
US (1) US20230059560A1 (https=)
EP (1) EP4093750A1 (https=)
JP (1) JP7777532B2 (https=)
KR (1) KR20220131262A (https=)
CN (1) CN115698048A (https=)
AU (1) AU2021211874A1 (https=)
BR (1) BR112022014272A2 (https=)
CA (2) CA3164500A1 (https=)
MX (1) MX2022008727A (https=)
PH (1) PH12022551792A1 (https=)
TW (1) TW202142254A (https=)
WO (1) WO2021148411A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980654B2 (en) 2020-09-22 2024-05-14 Wisconsin Alumni Research Foundation Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor
JP2024501821A (ja) 2020-12-23 2024-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓組織細胞に対する特異性を有するウイルスカプシドタンパク質
CN115820829B (zh) * 2022-03-22 2026-04-17 中国人民解放军军事科学院军事医学研究院 Mydgf在防治记忆损伤及其相关疾病中的应用
CA3258215A1 (en) 2022-06-03 2023-12-07 Boehringer Ingelheim International Gmbh RECOMBINANT EXPRESSION OF THE MYELOID-DERIVED GROWTH FACTOR
CN120112304A (zh) 2022-09-08 2025-06-06 勃林格殷格翰国际有限公司 用于治疗心源性休克的髓源性生长因子
EP4480490A1 (en) * 2023-06-23 2024-12-25 Medizinische Hochschule Hannover Brick1 for use in treating myocardial diseases
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
WO1997047358A1 (en) 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
JP2001506484A (ja) 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
AU4220797A (en) * 1996-09-13 1998-04-02 Protegene Inc. Human proteins having secretory signal sequences and DNAs encoding these prot eins
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US20080004232A1 (en) 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP2130547A1 (en) 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
EP3747457A3 (en) 2013-01-17 2021-03-03 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
KR20250133994A (ko) * 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
WO2020176732A1 (en) * 2019-02-27 2020-09-03 Icahn School Of Medicine At Mount Sinai TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY

Also Published As

Publication number Publication date
JP2023511358A (ja) 2023-03-17
TW202142254A (zh) 2021-11-16
EP4093750A1 (en) 2022-11-30
CA3164500A1 (en) 2021-07-29
WO2021148411A1 (en) 2021-07-29
MX2022008727A (es) 2022-10-07
JP7777532B2 (ja) 2025-11-28
BR112022014272A2 (pt) 2022-09-20
AU2021211874A1 (en) 2022-08-25
CA3223879A1 (en) 2021-07-29
CN115698048A (zh) 2023-02-03
PH12022551792A1 (en) 2023-09-18
US20230059560A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
KR20220131262A (ko) 섬유증, 비대 또는 심부전의 치료 또는 예방에 사용하기 위한 골수-유래 성장 인자
AU2020267282B2 (en) Compositions and methods for decreasing tau expression
KR102712656B1 (ko) Hsd17b13 변종 및 이것의 용도
JP4351896B2 (ja) ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法
KR20180016970A (ko) 타우 안티센스 올리고머와 그 용도
JP6960396B2 (ja) 分裂終了細胞の細胞分裂を誘発するための方法
KR102520654B1 (ko) 안티센스 올리고뉴클레오티드 및 당원병 Ia형 예방 또는 치료용 조성물
KR20160048103A (ko) Vegf-c 및 ccbe1의 치료적 용도
CN111032093A (zh) 控制心肌纤维化和重塑的方法和组合物
JPWO2004022753A1 (ja) アクチン関連新規細胞骨格タンパク質ｌａｃｓ
CN117441017A (zh) 用于治疗肝病的组合疗法
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
CN110167563A (zh) 用于调节心脏细胞功能的方法、相关核苷酸和化合物
CN113966341B (zh) Sghrt编码的多肽及相关产物、方法和用途
HK40088501A (zh) 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
EA053022B1 (ru) Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности
US20040197777A1 (en) Polymorphisms of the OCTN1 and OCTN2 cation transporters associated with inflammatory bowel disorders
KR20240149152A (ko) 안티센스 올리고뉴클레오티드 및 당원병 Ia형 예방 또는 치료용 조성물
KR102958345B1 (ko) Hsd17b13 변종 및 이것의 용도
Li et al. Knockdown of C3G Mitigates Post-Infarct Remodeling via Regulation of ERK1/2, Bcl-2 and Bax in Rat Myocardial Cells
RU2777570C2 (ru) Композиции и способы для снижения экспрессии tau
CA2982105C (en) Methods for inducing cell division of postmitotic cells
HK40105813A (zh) 用於治疗肝病的组合疗法
JP2007169223A (ja) アポトーシス促進剤およびそれを用いた医薬製剤
KR20260061292A (ko) Hsd17b13 변종 및 이것의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902